Navigation Links
Influenza Vaccine FluMist To Be Approved In Younger Children As Well

MedImmune, the company that has successfully sold flu vaccines to healthy adults in the age range of 5 to 49 is now poised on the edge of another victory . The U.S Food and Drug Administration is now about to approve the sale of FluMist targeting children younger than 5 years.

This announcement comes at a time when the company is planning to self itself to UKs AstraZeneca for 15.6 billion dollars. AstraZeneca was behind MedImmune because it did not have its own flu vaccine business. Once the deal closes, MedImmune becomes a wholly owned subsidiary of AstraZeneca.

The vaccine FluMist has had more than its share of hurdles, such as the preliminary safety concerns, being deemed unfit for young kids, and then storage problems as most pharmacies refused the drug as it needed to be stored in the freezer. This was overcome recently by a FDA-approved refrigerator safe version.

The newer version of MedImmune s FluMist appears effective for children younger than 5 years old, although safety data on the influenza vaccine is still under examination.

MedImmune sought FDA approval to market the spray for children ages 1 to 5 without a history of wheezing or asthma.

According to FDA documents, four studies conducted by MedImmune found the drug was effective against Type A and B influenza viruses, including one trial that showed the vaccine was about 90 percent effective.

Reviewers for the FDA also said one company study of the nasal spray vaccine did not signal any widespread safety problems, but results from other studies are still being reviewed. Those findings will be presented to the panel on Wednesday.

Though children who received FluMist experienced more wheezing than those who were given an inactive vaccine, "the difference between treatment groups is quite small," one reviewer said.

Other side effects included pneumonia, among other problems. Previously known side effects with FluMis t include nasal congestion, runny nose, sore throat and cough.

In a separate document, MedImmune claimed the vaccine's safety and efficacy were proven in children 24 to 59 months old and "that the risk-benefit profile for children 12 (to) 23 months of age without a history of wheeze or asthma warrants use of FluMist in this population as well."

It also said it would continue to monitor the drug in younger patients if approved.

FluMist competes with injectable flu vaccines made by GlaxoSmithKline Plc, Sanofi-Aventis' Sanofi Pasteur unit, and Chiron, which was recently acquired by Novartis AG.


'"/>




Related medicine news :

1. Influenza drug delayed
2. Chances are high for Avian Influenza virus altering its form
3. Influenza Avian Flu strain has become more contagious and dangerous.
4. A Vaccine for the impending pandemic Avian Influenza
5. Influenza Vaccination for children with neurological or neuromuscular disease
6. Avian Influenza: Government to set up expert committee
7. Resistant Influenza strains creates panic in US
8. Influenza Vaccination For The Elderly
9. Fao Declares Humans Spread Avian Influenza Virus
10. Statins Could Play Important Role In Influenza Pandemic
11. Zoo Animal Succumbs to Avian Influenza in Germany
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... concerning this present generation. Yisrayl makes an astounding statement when he says that ... explains that the Bible details the current times so plainly that anyone should be ...
(Date:2/24/2017)... ... 2017 , ... Congratulations to Head Over Heels’ elite gymnast ... Ms. Esparza qualified into this prestigious status after winning the Vault, Floor, ... Nevada. Frida is one of approximately 25 gymnasts in the nation who earns ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une ... d,annoncer les excellents résultats semestriels clos le 31 décembre ... présentation complète « Résultats et mise à jour sur la ... Faits marquants ... $ ; en hausse de 104 %) Bénéfice ...
Breaking Medicine Technology: